Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit

European Journal of Medicinal Chemistry

Volumn 63, Issue , 2013, Pages 811-825

  Suzuki, Hideyuki ^a   Utsunomiya, Iwao ^a   Shudo, Koichi ^a   Fukuhara, Norio ^b   Iwaki, Tsutomu ^b   Yasukata, Tatsuro ^b  

^a Kawasaki   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

1,2,5 Oxadiazepane; 1,2,5 Triazepane; Antibacterial; Oxazolidinone

Indexed keywords

5 (2 FLUORO 4 NITROPHENYL)[1,2,5]TRIAZEPANE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 5 (2,6 DIFLUORO 4 NITROPHENYL)[1,2,5]TRIAZEPANE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 5 (ACETYLAMINOMETHYL) 3 [3,5 DIFLUORO 4 ([1,2,5]OXADIAZEPAN 5 YL)PHENYL]OXAZOLIDIN 2 ONE; 5 (ISOXAZOL 3 YL AMINOMETHYL) 3 [3 FLUORO 4 [1 (HYDROXYACETYL)[1,2,5]TRIAZEPAN 5 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 (ISOXAZOL 3 YL AMINOMETHYL) 3 [3,5 DIFLUORO 4 ([1,2,5]OXADIAZEPAN 5 YL)PHENYL]OXAZOLIDIN 2 ONE; 5 (ISOXAZOL 3 YL AMINOMETHYL) 3 [3,5 DIFLUORO 4 [1 (HYDROXYACETYL)[1,2,5]TRIAZEPAN 5 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 (ISOXAZOL 3 YL AMINOMETHYL) 3 [3,5 DIFLUORO 4 [2 (HYDROXYACETYL)[1,2,5]OXADIAZEPAN 5 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 (THIOACETYLAMINOMETHYL) 3 [3,5 DIFLUORO 4 ([1,2,5]OXADIAZEPAN 5 YL)PHENYL]OXAZOLIDIN 2 ONE; 5 3 [4 (2[1,2,5]OXADIAZEPAN 5 YL) 3,5 DIFLUOROPHENYL] 5 (1,2,3 TRIAZOL 1 YLMETHYL)OXAZOLIDIN 2 ONE; 5 3 [4 [1 (HYDROXYACETYL)[1,2,5]TRIAZEPAN 5 YL] 3 FLUOROPHENYL] 5 (1,2,3 TRIAZOL 1 YLMETHYL)OXAZOLIDIN 2 ONE; 5 3 [4 [1 (HYDROXYACETYL)[1,2,5]TRIAZEPAN 5 YL] 3,5 DIFLUOROPHENYL] 5 (1,2,3 TRIAZOL 1 YLMETHYL)OXAZOLIDIN 2 ONE; 5 3 [4 [2 (HYDROXYACETYL)[1,2,5]OXADIAZEPAN 5 YL] 3,5 DIFLUOROPHENYL] 5 (1,2,3 TRIAZOL 1 YLMETHYL)OXAZOLIDIN 2 ONE; ANTIBIOTIC AGENT; CYTOCHROME P450 INHIBITOR; EPEREZOLID; LINEZOLID; MONOAMINE OXIDASE INHIBITOR; N [[3 [3 FLUORO 4 [1 (HYDROXYACETYL)[1,2,5]TRIAZEPAN 5 YL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL] O METHYLTHIOCARBAMATE); N [[3 [3 FLUORO 4 [1 (HYDROXYACETYL)[1,2,5]TRIAZEPAN 5 YL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; N [[3 [3 FLUORO 4 [1 (HYDROXYACETYL)[1,2,5]TRIAZEPAN 5 YL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]THIOACETAMIDE; N [[3 [3,5 DIFLUORO 4 [1 (HYDROXYACETYL)[1,2,5]TRIAZEPAN 5 YL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL] O METHYLTHIOCARBAMATE; N [[3 [3,5 DIFLUORO 4 [1 (HYDROXYACETYL)[1,2,5]TRIAZEPAN 5 YL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; N [[3 [3,5 DIFLUORO 4 [1 (HYDROXYACETYL)[1,2,5]TRIAZEPAN 5 YL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]THIOACETAMIDEN; N [[3 [3,5 DIFLUORO 4 [2 (HYDROXYACETYL)[1,2,5]OXADIAZEPAN 5 YL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL] O METHYLTHIOCARBAMATE; N [[3 [3,5 DIFLUORO 4 [2 (HYDROXYACETYL)[1,2,5]OXADIAZEPAN 5 YL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDEN; N [[3 [3,5 DIFLUORO 4 [2 (HYDROXYACETYL)[1,2,5]OXADIAZEPAN 5 YL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]THIOACETAMIDE; O METHYL [N [3 (4[1,2,5]OXADIAZEPAN 5 YL) 3,5 DIFLUOROPHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYLTHIOCARBAMATE; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MOUSE; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; MONOAMINE OXIDASE; OXAZOLIDINONES; PROSENCEPHALON; RATS; STAPHYLOCOCCAL INFECTIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84876013028     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.03.003     Document Type: Article

References (52)

1. C.M. Perry, and B. Jarvis Linezolid a review of its use in the management of serious gram-positive infections Drugs 61 2001 525 551
2. R.C. Moellering Jr. Linezolid: the first oxazolidinone antimicrobial Ann Intern Med. 138 2003 135 142
3. A.H. Lin, R.W. Murray, T.J. Vidmar, and K.R. Marotti The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin Antimicrob. Agents Chemother. 41 1997 2127 2131
4. M.R. Barbachyn, and C.W. Ford Oxazolidinone structure-activity relationships leading to linezolid Angew. Chem. Int. Ed. 42 2003 2010 2023
5. A. Holý, B. Otová, M. Buděší nský, D. Emerson, and M.E. Wiles O-Phosphonatomethylcholine, its analogues, alkyl esters, and their biological activity J. Med. Chem. 44 2001 4462 4467
6. A. Lupp, J. Wange, H. Oelschläger, and C. Fleck Pharmacological and toxicological testing of the enantiomers of two chiral fomocaine alkylmorpholine derivatives in comparison to their in vitro interactions on drug metabolism in rats Arzeim.-Forsch. 56 2006 369 376
7. A. Trabocchi, I. Stefanini, M. Morvillo, L. Ciofi, D. Cavalieri, and A. Guarna Chemical genetics approach to identify new small molecule modulators of cell growth by phenotypic screening of Saccharomyces cerevisiae strains with a library of morpholine-derived compounds Org. Biomol. Chem. 8 2010 5552 5557
8. C.A. Dvorak, R. Apodaca, W. Xiao, J.A. Jablonowski, P. Bonaventure, C. Dugovic, J. Shelton, B. Lord, K. Miller, L.K. Dvorak, T.W. Lovenberg, and N.I. Carruthers Diamine-based human histamine H3 receptor antagonists: (4-aminobutyn-1-yl)benzylamines Eur. J. Med. Chem. 44 2009 4098 4106
9. R. Perrone, F. Berardi, N.A. Colabufo, M. Leopoldo, E. Lacivita, and V. Tortorella Trans-4-[4-(methoxyphenyl)cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT1A receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1- arylpiperazines J. Med. Chem. 44 2001 4431 4442
10. I.O. Donkor, T.L. Huang, B. Tao, D. Rattendi, S. Lane, M. Vargas, B. Goldberg, and C. Bacchi Trypanocidal activity of conformationally restricted pentamidine congeners J. Med. Chem. 46 2003 1041 1048
11. Y. Osa, S. Kobayashi, Y. Sato, Y. Suzuki, K. Takino, T. Takeuchi, Y. Miyata, M. Sakaguchi, and H. Takayanagi Structural properties of dibenzosuberanylpiperazine derivatives for efficient reversal of chloroquine resistance in Plasmodium chabaudi J. Med. Chem. 46 2003 1948 1956
12. J. Guillon, P. Grellier, M. Labaied, P. Sonnet, J.-M. Léger, R. Déprez-Poulain, I. Forfar-Bares, P. Dallemagne, N. Lemaitre, F. Péhourcq, J. Rochette, C. Sergheraert, and C. Jarry Synthesis, antimalarial activity, and molecular modeling of new pyrrolo[1,2-a]quinoxalines, bispyrrolo[1,2-a]quinoxalines, bispyrido[3,2-e]pyrrolo[1,2-a]pyrazines, and bispyrrolo[1,2-a]thieno[3,2-e]pyrazines J. Med. Chem. 47 2004 1997 2009
13. N. Serradji, M. Martin, O. Bensaid, S. Cisternino, C. Rousselle, N. Dereuddre-Bosquet, J. Huet, C. Redeuilh, A. Lamouri, C.-Z. Dong, P. Clayette, J.-M. Scherrmann, D. Dormont, and F. Heymans Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity J. Med. Chem. 47 2004 6410 6419
14. P. Grundt, E.E. Carlson, J. Cao, C.J. Bennett, E. McElveen, M. Taylor, R.R. Luedtke, and A.H. Newman Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor J. Med. Chem. 48 2005 839 848
15. A.E. Shchekotikhin, A.A. Shtil, Y.N. Luzikov, T.V. Bobrysheva, V.N. Buyanovc, and M.N. Preobrazhenskaya 3-Aminomethyl derivatives of 4,11-dihydroxynaphtho[2,3-f]indole-5,10-dione for circumvention of anticancer drug resistance Bioorg. Med. Chem. 13 2005 2285 2291
16. A. Foroumadi, S. Emami, S. Pournourmohammadi, A. Kharazmi, and A. Shafiee Synthesis and in vitro leishmanicidal activity of 2-(1-methyl-5-nitro-1H- imidazol-2-yl)-5-substituted-1,3,4-thiadiazole derivatives Eur. J. Med. Chem. 40 2005 1346 1350
17. A.S. Mehanna, and J.Y. Kim Design, synthesis, and biological testing of thiosalicylamides as a novel class of calcium channel blockers Bioorg. Med. Chem. 13 2005 4323 4331
18. T. Kálai, M. Khan, M. Balog, V.K. Kutala, P. Kuppusamy, and K. Hideg Structure-activity studies on the protection of trimetazidine derivatives modified with nitroxides and their precursors from myocardial ischemia-reperfusion injury Bioorg. Med. Chem. 14 2006 5510 5516
19. X. Barril, M.C. Beswick, A. Collier, M.J. Drysdale, B.W. Dymock, A. Fink, K. Grant, R. Howes, A.M. Jordan, A. Massey, A. Surgenor, J. Wayne, P. Workmanb, and L. Wrighta 4-Amino derivatives of the Hsp90 inhibitor CCT018159 Bioorg. Med. Chem. Lett. 16 2006 2543 2548
20. R.P. Tangallapally, R.E.B. Lee, A.J.M. Lenaerts, and R.E. Lee Synthesis of new and potent analogues of anti-tuberculosis agent 5-nitro-furan-2- carboxylic acid 4-(4-benzyl-piperazin-1-yl)-benzylamide with improved bioavailability Bioorg. Med. Chem. Lett. 16 2006 2584 2589
21. M.J. Fray, G. Bish, P.V. Fish, A. Stobie, F. Wakenhut, and G.A. Whitlock Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors Bioorg. Med. Chem. Lett. 16 2006 4349 4353
22. J.N.N.S. Chandra, C.T. Sadashiva, C.V. Kavitha, and K.S. Rangappa Synthesis and in vitro antimicrobial studies of medicinally important novel N-alkyl and N-sulfonyl derivatives of 1-[bis(4-fluorophenyl)-methyl]piperazine Bioorg. Med. Chem. 14 2006 6621 6627
23. P. Chaudhary, S. Nimesh, V. Yadav, A.K. Verma, and R. Kumar Synthesis, characterization and in vitro biological studies of novel cyano derivatives of N-alkyl and N-aryl piperazine Eur. J. Med. Chem. 42 2007 471 476
24. S.M. Sondhi, S. Jain, M. Dinodia, R. Shukla, and R. Raghubir One pot synthesis of pyrimidine and bispyrimidine derivatives and their evaluation for anti-inflammatory and analgesic activities Bioorg. Med. Chem. 15 2007 3334 3344
25. C.W. am Ende, S.E. Knudson, N. Liu, J. Childs, T.J. Sullivan, M. Boyne, H. Xu, Y. Gegina, D.L. Knudson, F. Johnson, C.A. Peloquin, R.A. Slaydend, and P.J. Tonge Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors Bioorg. Med. Chem. Lett. 18 2008 3029 3033
26. Y. Hirokawa, H. Kinoshita, T. Tanaka, T. Nakamura, K. Fujimoto, S. Kashimoto, T. Kojima, and S. Kato Pleuromutilin derivatives having a purine ring. Part 3: synthesis and antibacterial activity of novel compounds possessing a piperazine ring spacer Bioorg. Med. Chem. Lett. 19 2009 175 179
27. G. Aridoss, P. Parthiban, R. Ramachandran, M. Prakash, S. Kabilan, and Y.T. Jeong Synthesis and spectral characterization of a new class of N-(N-methylpiperazinoacetyl)-2,6-diarylpiperidin-4-ones: antimicrobial, analgesic and antipyretic studies Eur. J. Med. Chem. 44 2009 577 592
28. S. Jazayeri, M.H. Moshafi, L. Firoozpour, S. Emami, S. Rajabalian, M. Haddad, F. Pahlavanzadeh, M. Esnaashari, A. Shafiee, and A. Foroumadi Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids Eur. J. Med. Chem. 44 2009 1205 1209
29. O.K. Onajole, K. Govender, P. Govender, P.D. van Helden, H.G. Kruger, G.E.M. Maguire, K. Muthusamy, M. Pillay, I. Wiid, and T. Govender Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent anti-tuberculosis agents Eur. J. Med. Chem. 44 2009 4297 4305
30. K.-X. Chen, Z.-G. Li, H.-Y. Xie, J.-R. Gao, and J.-W. Zou Quantitative structure-activity relationship analysis of aryl alkanol piperazine derivatives with antidepressant activities Eur. J. Med. Chem. 44 2009 4367 4375
31. K.T. Nguyen, E. Luethi, S. Syed, S. Urwyler, S. Bertrand, D. Bertrand, and J.-L. Reymond 3-(Aminomethyl)piperazine-2,5-dione as a novel NMDA glycine site inhibitor from the chemical universe database GDB Bioorg. Med. Chem. Lett. 19 2009 3832 3835
32. R. Di Fabio, C. Griffante, G. Alvaro, G. Pentassuglia, D.A. Pizzi, D. Donati, T. Rossi, G. Guercio, M. Mattioli, Z. Cimarosti, C. Marchioro, S. Provera, L. Zonzini, D. Montanari, S. Melotto, P.A. Gerrard, D.G. Trist, E. Ratti, and M. Corsi Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis- trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor Antagonist J. Med. Chem. 52 2009 3238 3247
33. N. Basse, M. Montes, X. Maréchal, L. Qin, M. Bouvier-Durand, E. Genin, J. Vidal, B.O. Villoutreix, and M. Reboud-Ravaux Novel organic proteasome inhibitors identified by virtual and in vitro screening J. Med. Chem. 53 2010 509 513
34. T. Kobayashi, S. Sasaki, N. Tomita, S. Fukui, M. Nakayama, A. Kiba, M. Kusaka, S. Matsumoto, M. Yamaguchi, F. Itoh, and A. Baba 2-Acylamino-4,6- diphenylpyridine derivatives as novel GPR54 antagonists with good brain exposure and in vivo efficacy for plasma LH level in male rats Bioorg. Med. Chem. 18 2010 5157 5171
35. B. Ghosh, T. Antonio, B. Gopishetty, M. Reith, and A. Dutta Further delineation of hydrophobic binding sites in dopamine D2/D3 receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl- piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol Bioorg. Med. Chem. 18 2010 5661 5674
36. J.Y. Kim, S.Y. Kang, H.J. Kim, M.E. Jung, E.-J. Son, J. Kim, J. Lee, D. Kim, W.-K. Park, and A.N. Pae Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT2A, 5-HT2C, and the serotonin transporter as a potential antidepressant Bioorg. Med. Chem. Lett. 20 2010 6439 6442
37. Y.B. Lee, Y.-D. Gong, H. Yoon, C.-H. Ahn, M.-K. Jeon, and J.-Y. Kong Synthesis and anticancer activity of new 1-[(5 or 6-substituted-2- alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives Bioorg. Med. Chem. 18 2010 7966 7974
38. H. Xiong, T.A. Brugel, M. Balestra, D.G. Brown, K.A. Brush, C. Hightower, L. Hinkley, V. Hoesch, J. Kang, G.M. Koether, J.P. McCauley Jr., F.M. McLaren, L.M. Panko, T.R. Simpson, R.W. Smith, J.M. Woods, B. Brockel, V. Chhajlani, R.A. Gadient, N. Spear, L.A. Sygowski, M. Zhang, J. Arora, N. Breysse, J.M. Wilson, M. Isaac, A. Slassi, and M.M. King 4-Aryl piperazine and piperidine amides as novel mGluR5 positive allosteric modulators Bioorg. Med. Chem. Lett. 20 2010 7381 7384
39. J. Xu, Y. Cao, J. Zhang, S. Yu, Y. Zou, X. Chai, Q. Wu, D. Zhang, Y. Jiang, and Q. Sun Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives Eur. J. Med. Chem. 46 2011 3142 3148
40. G. Palermo, D. Branduardi, M. Masetti, A. Lodola, M. Mor, D. Piomelli, A. Cavalli, and M. De Vivo Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas J. Med. Chem. 54 2011 6612 6623
41. D.J. Richard, J.C. Verheijen, K. Curran, J. Kaplan, L. Toral-Barza, I. Hollander, J. Lucas, K. Yu, and A. Zask Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability Bioorg. Med. Chem. Lett. 19 2009 6830 6835
42. K. Szotor Synthesis of hexahydrotriazepine-1, 2, 5 derivatives Diss. Pharm. Pharmacol. 24 1972 385 388
43. H. Suzuki, I. Utsunomiya, and K. Shudo Synthesis and application of [1,2,5]triazepane and [1,2,5]oxadiazepane as versatile structural units for drug discovery Chem. Pharm. Bull. 58 2010 1001 1002
44. M.R. Barbachyn, D.S. Toops, K.C. Grega, S.K. Hendges, C.W. Ford, G.E. Zurenko, J.C. Hamel, J.D. Schaadt, D. Stapert, B.H. Yagi, J.M. Buysse, W.F. Demyan, J.O. Kilburn, and S.E. Glickman Synthesis and antibacterial activity of new tropone substituted phenyloxazolidinone antibacterial agents. 2. Modification of the phenyl ring-the potentiating effect of fluorine substitution on in vivo activity Bioorg. Med. Chem. Lett. 6 1996 1009 1014
45. W.A. Gregory, D.R. Brittelli, C.-L.J. Wang, M.A. Wuonola, R.J. McRipley, D.C. Eustice, V.S. Eberly, P.T. Bartholomew, A.M. Slee, and M. Forbes Antibacterials. Synthesis and structure-activity studies of 3-aryl-2- oxooxazolidines. 1. The "B" group J. Med. Chem. 32 1989 1673 1681
46. L.M. Thomasco, R.C. Gadwood, E.A. Weaver, J.M. Ochoada, C.W. Ford, G.E. Zurenko, J.C. Hamel, D. Stapert, J.K. Moerman, R.D. Schaadt, and B.H. Yagi The synthesis and antibacterial activity of 1,3,4-thiadiazole phenyl oxazolidinone analogues Bioorg. Med. Chem. Lett. 13 2003 4193 4196
47. R. Tokuyama, Y. Takahashi, Y. Tomita, M. Tsubouchi, N. Iwasaki, N. Kado, E. Okezaki, and O. Nagata Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 3. Synthesis and evaluation of 5-thiocarbamate oxazolidinones Chem. Pharm. Bull. 49 2001 361 367
48. F. Reck, F. Zhou, M. Girardot, G. Kern, C.J. Eyermann, N.J. Hales, R.R. Ramsay, and M.B. Gravestock Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A J. Med. Chem. 48 2005 499 506
49. S.I. Hauck, C. Cederberg, A. Doucette, L. Grosser, N.J. Hales, G. Poon, and M.B. Gravestock New carbon-linked azole oxazolidinones with improved potency and pharmacokinetics Bioorg. Med. Chem. Lett. 17 2007 337 340
50. S. Tsiodras, H.S. Gold, G. Sakoulas, G.M. Eliopoulos, C. Wennersten, L. Venkataraman, R.C. Moellering Jr., and M.J. Ferraro Linezolid resistance in a clinical isolate of Staphylococcus aureus Lancet 358 2001 207 208
51. M. Tsuji, M. Takema, H. Miwa, J. Shimada, and S. Kuwahara In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models Antimicrob. Agents Chemother. 47 2003 2507 2512
52. O. Curet, G. Damoiseau, N. Aubin, N. Sontag, V. Rovei, and F.X. Jarreau Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile J. Pharmacol. Exp. Ther. 277 1996 253 264